Objetivo é reforçar a importância do equilíbrio emocional dos profissionais que estão na linha de frente do combate à pandemia Leia Mais »

Companhia foi destaque no ranking Saúde e Bem-Estar Leia Mais »

Zejula, recém-lançado pela farmacêutica GSK, reduz em até 73% o risco de progressão da doença ou óbito, proporcionando às pacientes maior expectativa e qualidade de vida1,2 Leia Mais »

26 August 2021

A study led by University of Birmingham experts has been awarded the Guinness World Records title for the world’s largest scientific collaboration – involving over 140,000 patients in 116 countries.

The record for ‘Most authors on a single peer-reviewed academic paper’ is now held by the Universities of Birmingham and Edinburgh after 15,025 scientists around the globe contributed to major research into the impact of COVID-19 on surgical patients.

Funded by the NIHR, the researchers concluded that patients waiting for elective surgery should be treated as a vulnerable group and access COVID-19 vaccines ahead of the general population – potentially helping to avoid thousands of post-operative deaths linked to the virus.

This could be particularly important for Low- and Middle-income Countries (LMICs) where access to vaccination remains limited and mitigation measures such as nasal swab screening and COVID-free surgical pathways to reduce the risk of virus-related complications are not available for many patients.

Overall, the scientists estimated that global prioritisation of pre-operative vaccination for elective patients could prevent an additional 58,687 COVID-19-related deaths in one year.

The COVIDSurg Collaborative international team of researchers published its findings in BJS, Europe’s leading surgical journal, after studying data from 1,667 hospitals in countries including Australia, Brazil, China, India, UAE, UK and USA.

Study co-lead author Mr Aneel Bhangu, a surgeon from the University of Birmingham, commented: “Being awarded the Guinness World Records title for the world’s largest scientific collaboration highlights the scale of our global partnership, which aims to contribute to our understanding of COVID-19 and help to save as many lives as possible around the world.

“It marks the commitment and hard work of thousands of medical colleagues around the world to understand the changes that are needed in how surgery must be delivered if we are to beat the virus and reduce its impact on surgical patients.”

Before the COVID-19 pandemic, five billion people lacked access to surgical care and 143 million more operations per year were required globally. There was already a major global inequity in access to safe and affordable surgery across low and middle-income countries, with an urgent need to expand capacity.  The pandemic has acutely worsened that situation.

Launched in March 2020, the COVIDSurg Collaborative has provided data needed to support changes to surgical delivery in the fastest time frame ever seen by a surgical research group. Research from this huge study group has also explored the timing of surgery after COVID infection, preoperative isolation, and risks of blood clots, all published in the field-leading journal Anaesthesia.

Co-author Mr James Glasbey, also a surgical trainee from the University of Birmingham, commented: “Over 15,000 surgeons and anaesthetists from across 116 countries came together to contribute to this study making it the largest ever scientific collaboration, surpassing even ground-breaking research from the Large Hadron Collider at CERN in Switzerland. Every day we hear in the news that waiting lists are growing, and patients are unable to access the surgery that they need. This situation sadly is deteriorating in countries all over the world. Policy makers can use the data from this scientific collaboration to safely restart elective surgery.”

During the first wave of the pandemic, up to 70% of elective surgeries were postponed, resulting in an estimated 28 million procedures being delayed or cancelled. Whilst surgery volumes have started to recover in many countries, ongoing disruption is likely to continue throughout 2021, particularly in the event of countries experiencing further waves of COVID-19. Vaccination is also likely to decrease post-operative pulmonary complications – reducing intensive care use and overall healthcare costs.

Pfizer e BioNTech anunciaram nesta quinta-feira (26) a assinatura de uma carta de intenção com a farmacêutica brasileira Eurofarma para fabricação local da sua vacina contra Covid-19 e distribuição na América Latina. Leia Mais »

Após 10 meses de inauguração do armazém vertical, foi registrado o aumento de 35% na produtividade da planta de Pernambuco Leia Mais »

A multinacional com sede no Brasil inclui em seu portfólio experiente diretor financeiro com 30 anos de mercado Leia Mais »

Sistemas de climatização e purificadores de ar portáteis podem contribuir para uma melhor qualidade para o ar interno em ambientes fechados em tempos de clima seco e queimadas. Leia Mais »

Primeira ação social da iniciativa Juntos ocorreu no início de agosto para oferecer suporte logístico e aprimoramento profissional à equipe de saúde comunitária da estância paulista. Ação foi motivada após diversos casos de perda de vacinas no país. Leia Mais »

O evento on-line será destinado a médicos, enfermeiros e outros profissionais de saúde Leia Mais »